{"id":"matching-placebo-to-ustekinumab","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Matching placebo serves as a control in phase 3 trials to evaluate the efficacy and safety of ustekinumab, an IL-12/IL-23 inhibitor. The placebo is formulated to be indistinguishable from the active drug in terms of appearance, taste, and injection characteristics, enabling proper blinding of study participants and investigators. This allows for accurate assessment of ustekinumab's true therapeutic benefit independent of placebo effect.","oneSentence":"This is a placebo formulation designed to match the appearance and administration route of ustekinumab for blinded clinical trial comparison.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:16.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06934226","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-04-15","conditions":"Plaque Psoriasis","enrollment":752},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT04978493","phase":"PHASE2","title":"A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-02","conditions":"Crohn Disease","enrollment":49},{"nctId":"NCT04630028","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-17","conditions":"Colitis, Ulcerative","enrollment":112},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT03517722","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-16","conditions":"Lupus Erythematosus, Systemic","enrollment":516},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT02407236","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-10","conditions":"Colitis, Ulcerative, Inflammatory Bowel Diseases","enrollment":961},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT04060888","phase":"PHASE3","title":"A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-14","conditions":"Lupus Erythematosus, Systemic","enrollment":""},{"nctId":"NCT03881059","phase":"PHASE2","title":"Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-04-01","conditions":"Active Psoriatic Arthritis","enrollment":203},{"nctId":"NCT01090427","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Psoriasis","enrollment":110},{"nctId":"NCT00955279","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-11","conditions":"Sarcoidosis","enrollment":173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo to Ustekinumab","genericName":"Matching Placebo to Ustekinumab","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}